These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20384543)

  • 1. Emerging biotherapies for Sjögren's syndrome.
    Tobón GJ; Saraux A; Pers JO; Youinou P
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):269-82. PubMed ID: 20384543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B cell-targeted therapies in Sjögren's syndrome.
    Tobón GJ; Pers JO; Youinou P; Saraux A
    Autoimmun Rev; 2010 Feb; 9(4):224-8. PubMed ID: 19671451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential for B-cell modulation in Sjögren's syndrome.
    Mariette X
    Rheum Dis Clin North Am; 2008 Nov; 34(4):1025-33, x. PubMed ID: 18984420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of B cell-targeted therapies in Sjögren's syndrome.
    Cornec D; Saraux A; Devauchelle-Pensec V; Clodic C; Pers JO
    Immunotherapy; 2013 Jun; 5(6):639-46. PubMed ID: 23725286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab therapy in primary Sjögren's syndrome.
    Alcântara C; Gomes MJ; Ferreira C
    Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
    Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
    Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic treatment in Sjögren's syndrome.
    Sada PR; Isenberg D; Ciurtin C
    Rheumatology (Oxford); 2015 Feb; 54(2):219-30. PubMed ID: 25342375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging biological therapies in primary Sjogren's syndrome.
    Ramos-Casals M; Brito-Zerón P
    Rheumatology (Oxford); 2007 Sep; 46(9):1389-96. PubMed ID: 17586555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.
    Abdulahad WH; Kroese FG; Vissink A; Bootsma H
    J Autoimmun; 2012 Aug; 39(1-2):103-11. PubMed ID: 22341852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [B lymphocytes in Sjögren's syndrome].
    Pers JO; Le Pottier L; Devauchelle V; Saraux A; Youinou P
    Rev Med Interne; 2008 Dec; 29(12):1000-6. PubMed ID: 18403061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the diagnosis and concept of Sjögren's syndrome (autoimmune exocrinopathy).
    Strand V; Talal N
    Bull Rheum Dis; 1979-1980; 30(9):1046-52. PubMed ID: 398729
    [No Abstract]   [Full Text] [Related]  

  • 12. Pathogenesis of Sjögren's syndrome and therapeutic consequences.
    Mariette X; Gottenberg JE
    Curr Opin Rheumatol; 2010 Sep; 22(5):471-7. PubMed ID: 20671520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune diseases and Sjogren's syndrome: an autoimmune exocrinopathy.
    Fox PC
    Ann N Y Acad Sci; 2007 Mar; 1098():15-21. PubMed ID: 17332090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
    Meijer JM; Meiners PM; Vissink A; Spijkervet FK; Abdulahad W; Kamminga N; Brouwer E; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoregulation in Sjögren's syndrome: influence of serum factors on T-cell subpopulations.
    Moutsopoulos HM; Fauci AS
    J Clin Invest; 1980 Feb; 65(2):519-28. PubMed ID: 6444308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
    Guzman Moreno R
    Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias.
    Tzioufas AG; Voulgarelis M
    Best Pract Res Clin Rheumatol; 2007 Dec; 21(6):989-1010. PubMed ID: 18068857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfer of Sjögren's syndrome-like autoimmune lesions into SCID mice and prevention of lesions by anti-CD4 and anti-T cell receptor antibody treatment.
    Hayashi Y; Haneji N; Hamano H; Yanagi K
    Eur J Immunol; 1994 Nov; 24(11):2826-31. PubMed ID: 7957574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An important role for B-cell activation factor and B cells in the pathogenesis of Sjögren's syndrome.
    Mackay F; Groom JR; Tangye SG
    Curr Opin Rheumatol; 2007 Sep; 19(5):406-13. PubMed ID: 17762603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
    Saraux A
    Autoimmun Rev; 2010 Jul; 9(9):609-14. PubMed ID: 20452466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.